Cost-effectiveness of Tyrosine Kinase Inhibitor Treatment Strategies for Chronic Myeloid Leukemia in Chronic Phase After Generic Entry of Imatinib in the United States

Changing the cost of care for chronic myeloid leukemia: the availability of generic imatinib in the USA and the EU

(2015) Rena M. Conti et al.   ANNALS OF HEMATOLOGY

Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study

(2014) N. P. Shah et al.   BLOOD

The Ethics Of ‘Fail First’: Guidelines And Practical Scenarios For Step Therapy Coverage Policies

(2014) Rahul K. Nayak et al.   HEALTH AFFAIRS

Chronic Myeloid Leukemia–Transplantation in the Tyrosine Kinase Era

(2014) Andrew J. Innes et al.   HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA

Clinical efficacy of generic imatinib

(2014) Mario L de Lemos et al.   JOURNAL OF ONCOLOGY PHARMACY PRACTICE

High Cancer Drug Prices in the United States: Reasons and Proposed Solutions

(2014) Hagop Kantarjian et al.   Journal of Oncology Practice

Economic Savings Versus Health Losses: The Cost-Effectiveness of Generic Antiretroviral Therapy in the United States

(2013) Rochelle P. Walensky et al.   ANNALS OF INTERNAL MEDICINE

European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013

(2013) M. Baccarani et al.   BLOOD

Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib

(2013) T. P. Hughes et al.   BLOOD

Measuring the symptom burden associated with the treatment of chronic myeloid leukemia

(2013) L. A. Williams et al.   BLOOD

Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION)

(2013) E. Jabbour et al.   BLOOD

The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts

(2013)   BLOOD

Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study

(2013) D. M. Ross et al.   BLOOD

Deep Molecular Response in Chronic Myeloid Leukemia: The New Goal of Therapy?

(2013) F.-X. Mahon et al.   CLINICAL CANCER RESEARCH

Loss of Major Molecular Response As a Trigger for Restarting Tyrosine Kinase Inhibitor Therapy in Patients With Chronic-Phase Chronic Myelogenous Leukemia Who Have Stopped Imatinib After Durable Undetectable Disease

(2013) Philippe Rousselot et al.   JOURNAL OF CLINICAL ONCOLOGY

Cost Sharing and Adherence to Tyrosine Kinase Inhibitors for Patients With Chronic Myeloid Leukemia

(2013) Stacie B. Dusetzina et al.   JOURNAL OF CLINICAL ONCOLOGY

Economic benefits of adequate molecular monitoring in patients with chronic myelogenous leukemia

(2013) Annie Guérin et al.   JOURNAL OF MEDICAL ECONOMICS

A review of the differences and similarities between generic drugs and their originator counterparts, including economic benefits associated with usage of generic medicines, using Ireland as a case study

(2013) Suzanne Dunne et al.   BMC Pharmacology & Toxicology

Costs and Cost-Effectiveness of Hematopoietic Cell Transplantation

(2012) Jaime M. Preussler et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Prediction of outcomes in patients with Ph+ chronic myeloid leukemia in chronic phase treated with nilotinib after imatinib resistance/intolerance

(2012) E Jabbour et al.   LEUKEMIA

Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population

(2011) F. Efficace et al.   BLOOD

Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy

(2011) A. R. Ibrahim et al.   BLOOD

Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS)

(2010) T. P. Hughes et al.   BLOOD

Adherence Is the Critical Factor for Achieving Molecular Responses in Patients With Chronic Myeloid Leukemia Who Achieve Complete Cytogenetic Responses on Imatinib

(2010) David Marin et al.   JOURNAL OF CLINICAL ONCOLOGY

Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial

(2010) François-Xavier Mahon et al.   LANCET ONCOLOGY

Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia

(2010) Hagop Kantarjian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia

(2010) Giuseppe Saglio et al.   NEW ENGLAND JOURNAL OF MEDICINE

Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study

(2009) L. Noens et al.   BLOOD

Projected economic impact of clinical findings of generic entry of topiramate on G4 European countries

(2009) Pierre Emmanuel Paradis et al.   CURRENT MEDICAL RESEARCH AND OPINION

A Multinational Study of Health State Preference Values Associated with Chronic Myelogenous Leukemia

(2009) Shelagh M. Szabo et al.   VALUE IN HEALTH

European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor

(2008) D. Marin et al.   BLOOD

Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib

(2008) A Hochhaus et al.   LEUKEMIA